ClinicalTrials.gg
RecruitingNCT05570019EVTI-PADUpdated Mar 13, 2024

Evaluation of Tissue Perfusion in Peripheral Arterial Disease (EVTI-PAD)

An observational study in Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia and Critical Limb Ischemia, sponsored by Medical University Innsbruck. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's listed conditions name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Medical University Innsbruck · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Chronic Limb-Threatening Ischemia with a site in Austria — 3 open to participants now, 4 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Austria.

Started
2022
the only one that year
Observational
3 of 17
2 open now
Registered
13th of 17
by date
Lead sponsor
1 of 17
Medical University Innsbruck

Among the 17 studies in Chronic Limb-Threatening Ischemia with a site in Austria, this one is the only one that started in 2022, is one of 3 observational ones, and was the 13th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

3 of the 17 studies in Chronic Limb-Threatening Ischemia with a site in Austria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Chronic Limb-Threatening Ischemia with a site in Austria, or all of them as a file.
02

Study summary

In this prospective single-center observational study, arterial perfusion in patients with lower limb peripheral arterial disease will be assessed with standard diagnostic tools (toe pressure, trans-cutaneous oxygen pressure, ankle-brachial index and fluorescence angiography) before and after standard revascularization procedures (open surgery and/or angioplasty).

Read the detailed description

Arterial perfusion is an important parameter for the capacity of wound healing in patients with peripheral arterial disease (PAD). Quantifying tissue perfusion in affected patients can help in deciding whether further revascularization is necessary to achieve wound healing and limb salvage. Not only in PAD patients with ulceration, but also in patients with rest pain or life-style limiting claudication, the measurement of arterial perfusion before and after revascularization could influence further treatment regarding surgical/interventional procedures as well as medical treatment. Digital subtraction angiography (DSA) is the gold standard for the evaluation of peripheral arterial outflow and for quality assessment after revascularization. However, angiography only displays the larger arteries and not tissue perfusion itself, which is crucial for wound healing. In this study, the change of tissue perfusion measured with the different standard diagnostic tools (toe pressure, trans-cutaneous oxygen pressure, ankle-brachial index and fluorescence angiography) before and after standard revascularization procedures will be evaluated.

03

Conditions studied

  • Peripheral Arterial Disease
  • Chronic Limb-Threatening Ischemia
  • Critical Limb Ischemia

Browse trials for

Keywords

  • Tissue perfusion
  • Peripheral arterial disease
  • Critical limb threatening ischemia
  • Critical limb ischemia
  • Fluorescence angiography
  • Fluorescence imaging
  • Indocyanine green
  • Microcirculation
04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's planned enrollment of 200 is above the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Medical University Innsbruck is the lead sponsor of 187 studies on the registry; 48 are open to participants now.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptomatic peripheral arterial disease (Rutherford categories 3-6) requiring revascularization procedures (open surgery and/or angioplasty).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with symptomatic peripheral arterial disease (Rutherford categories 3-6) requiring revascularization.

Exclusion criteria

Exclusion Criteria:

  • patients younger than 18 years
  • patients unable to give consent without legal guardians
  • iodine allergy
  • hyperthyroidism
  • allergy to indocyanine green
  • \<30ml/min/1.73m2
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • ProcedureRevascularization

    Open surgery (arterial endarterectomy with or without bypass surgery) and/or angioplasty (with or without stent placement)

07

What researchers measure

Primary outcomes

  1. Transcutaneous oxygen pressure

    Change in transcutaneous oxygen pressure is measured before and after the revascularization procedure.

    Time frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure

Secondary outcomes

  1. WIfI stage

    Change in WIfI (wound, ischemia, foot infection) stage is documented before and after the revascularization procedure.

    Time frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure

  2. Rutherford category

    Change in Rutherford category is documented before and after the revascularization procedure.

    Time frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure

  3. Primary patency

    Primary patency of the treated arterial lesion is documented after the procedure

    Time frame: Post-procedural (within 5 days) and 3 months after the index procedure

  4. Secondary patency

    Secondary patency of the treated arterial lesion is documented after the procedure

    Time frame: Post-procedural (within 5 days) and 3 months after the index procedure

  5. Limb salvage

    Limb salvage of the treated extremity is documented after the procedure

    Time frame: Post-procedural (within 5 days) and 3 months after the index procedure

  6. Ankle-brachial index (ABI)

    Change in ABI is documented before and after the revascularization procedure.

    Time frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure

  7. Fluorescence angiography

    Change in fluorescence angiography is documented before and after the revascularization procedure.

    Time frame: Pre-procedural, post-procedural (within 5 days) and 3 months after the index procedure

  8. Survival

    Survival of patients after the revascularization.

    Time frame: Post-procedural (within 5 days) and 3 months after the index procedure

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Halliday A, Bax JJ. The 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration With the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018 Mar;55(3):301-302. doi: 10.1016/j.ejvs.2018.03.004. No abstract available. PubMed 29579461 ↗
  • Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH, Aboyans V, Aksoy M, Alexandrescu VA, Armstrong D, Azuma N, Belch J, Bergoeing M, Bjorck M, Chakfe N, Cheng S, Dawson J, Debus ES, Dueck A, Duval S, Eckstein HH, Ferraresi R, Gambhir R, Gargiulo M, Geraghty P, Goode S, Gray B, Guo W, Gupta PC, Hinchliffe R, Jetty P, Komori K, Lavery L, Liang W, Lookstein R, Menard M, Misra S, Miyata T, Moneta G, Munoa Prado JA, Munoz A, Paolini JE, Patel M, Pomposelli F, Powell R, Robless P, Rogers L, Schanzer A, Schneider P, Taylor S, De Ceniga MV, Veller M, Vermassen F, Wang J, Wang S; GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019 Jul;58(1S):S1-S109.e33. doi: 10.1016/j.ejvs.2019.05.006. Epub 2019 Jun 8. Erratum In: Eur J Vasc Endovasc Surg. 2020 Mar;59(3):492-493. doi: 10.1016/j.ejvs.2019.11.025. Eur J Vasc Endovasc Surg. 2020 Jul;60(1):158-159. doi: 10.1016/j.ejvs.2020.04.033. PubMed 31182334 ↗
  • Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep;26(3):517-38. doi: 10.1016/s0741-5214(97)70045-4. Erratum In: J Vasc Surg 2001 Apr;33(4):805. PubMed 9308598 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Sep 2024, 23 months after the start.

Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 23 months is below that.

Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2022
First posted
Oct 6, 2022
StartActual
Oct 1, 2022
Primary completionEst.
Sep 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05570019
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Oct 1, 2022
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 13, 2024

Study contacts

Florian K Enzmann, MD, PhD
Contact
florian.enzmann@i-med.ac.at
004343512504 ext. 82196
Michaela Kluckner, MD
Contact
michaela.kluckner@i-med.ac.at
004343512504 ext. 83496

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion